SEC FORM 3

SEC Form 3

FORM 3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0104
Estimated average burden
hours per response:			0.5

1. Name and Address of Reporting Person^*

Lutzker Stuart

(Last)

(First)

(Middle)

C/O ARRIVENT BIOPHARMA, INC.

18 CAMPUS BOULEVARD, SUITE 100

(Street)

NEWTOWN SQUARE

19073

(City)

(State)

(Zip)

2. Date of Event Requiring Statement (Month/Day/Year)
01/25/2024

3. Issuer Name and Ticker or Trading Symbol
ArriVent Biopharma, Inc. [ AVBP ]

4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director	10% Owner
X	Officer (give title below)	Other (specify below)
	President of R&D

5. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned
1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)
Common Stock	147,744⁽¹⁾	D

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
1. Title of Derivative Security (Instr. 4)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
Stock Option (right to buy)	⁽²⁾	09/07/2031	Common Stock	65,746⁽³⁾	$2.28⁽³⁾	D
Stock Option (right to buy)	⁽⁴⁾	01/31/2032	Common Stock	24,983⁽³⁾	$2.28⁽³⁾	D
Stock Option (right to buy)	⁽⁴⁾	01/31/2032	Common Stock	42,735⁽³⁾	$2.28⁽³⁾	D
Stock Option (right to buy)	⁽⁵⁾	01/31/2033	Common Stock	42,734⁽³⁾	$3.65⁽³⁾	D
Stock Option (right to buy)	⁽⁶⁾	12/31/2033	Common Stock	49,309⁽³⁾	$7.76⁽³⁾	D

Explanation of Responses:

1. Reflects the 15.21-for-1 reverse stock split of the Issuer's common stock effected on January 23, 2024 in connection with the Issuer's initial public offering.

2. The shares underlying this option vested as to 25% on September 8, 2022, with the remainder vesting in 36 equal monthly installments thereafter, subject to the Reporting Person's continued service through the applicable vesting date.

3. Reflects the 15.21-for-1 reverse stock split of the Issuer's common stock effected on January 23, 2024 in connection with the Issuer's initial public offering, pursuant to which (i) the number of shares of common stock underlying the option was divided by 15.21 and (ii) the exercise price of the option was multiplied by 15.21.

4. The shares underlying this option vested as to 25% on February 1, 2023, with the remainder vesting in 36 equal monthly installments thereafter, subject to the Reporting Person's continued service through the applicable vesting date.

5. The shares underlying this option vest as to 25% on February 1, 2024, with the remainder vesting in 36 equal monthly installments thereafter, subject to the Reporting Person's continued service through the applicable vesting date.

6. The shares underlying this option vest as to 25% on January 1, 2025, with the remainder vesting in 36 equal monthly installments thereafter, subject to the Reporting Person's continued service through the applicable vesting date.

Remarks:

Exhibit 24.1 - Power of Attorney

	/s/ James Kastenmayer, Attorney-in-Fact for Stuart Lutzker	01/25/2024
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.